A positive SARS-CoV-2 IgG antibody test tells you that your immune system has produced a lasting class of antibodies in response to the virus, either through infection or vaccination. It does not, on its own, tell you how protected you are, when you were exposed, or whether you can still get sick. The gap between what the test measures and what people want it to mean is where most of the confusion lives, and closing that gap requires understanding a handful of practical details about timing, test targets, and the limits of any single number.
What an IgG Result Actually Represents
IgG is the most abundant antibody class in human blood and the one that sticks around longest after an immune challenge. In a SARS-CoV-2 infection, IgG antibodies typically become detectable within two to three weeks of symptom onset. In one study of Moroccan patients, about 79% had detectable IgG antibodies three months after symptoms began, with levels peaking around day 30 and remaining relatively stable through day 90.1PubMed Central. Kinetics of SARS-CoV-2 IgM and IgG Antibodies 3 Months after COVID-19 Onset in Moroccan Patients Unlike IgM, an earlier-arriving antibody that fades within weeks, IgG can persist for months or years, though its levels gradually decline.
A positive result means you have IgG antibodies against one or more parts of the SARS-CoV-2 virus above the test’s detection threshold. A negative result means your level falls below that threshold, not necessarily that you have zero antibodies or zero immune memory. This distinction matters because different tests use different thresholds, and some people mount detectable responses later or at lower levels than others.
Spike Versus Nucleocapsid Targets
Not all SARS-CoV-2 IgG tests measure the same thing. Most commercial assays target antibodies against one of two viral proteins: the spike protein (S) or the nucleocapsid protein (N). Which one your test measures changes what a positive result means.
The spike protein sits on the virus’s outer surface and is also the protein used in most COVID-19 vaccines. If your test detects anti-spike IgG, a positive result could mean you were infected, vaccinated, or both. The nucleocapsid protein, by contrast, is an internal structural protein not included in any widely used vaccine. A positive anti-N IgG result points specifically to a natural infection at some point.
This distinction has practical value. Someone who was vaccinated but never infected would be expected to have anti-spike IgG but no anti-nucleocapsid IgG. Someone who was infected and then vaccinated would have both. Researchers and clinicians have used this difference to sort out infection-derived immunity from vaccine-derived immunity in population studies.2Clinical Chemistry. Case-Control Study of Individuals with Discrepant Nucleocapsid and Spike Protein SARS-CoV-2 IgG Results If you are trying to figure out whether you had COVID at some earlier point despite being vaccinated, an anti-N test is the more informative one to request.
The two proteins also behave differently over time. Anti-nucleocapsid antibodies tend to peak around the fourth month after infection and then gradually decline, while anti-spike antibodies can keep rising for over a year in some people before waning.3Scientific Reports. Tracking the evolution of anti-SARS-CoV-2 antibodies and long-term humoral immunity within 2 years after COVID-19 infection So a negative anti-N result taken many months after infection does not necessarily mean infection never happened; the antibodies may have simply faded below the detection line.
How Accurate Are These Tests
Accuracy in antibody testing has two dimensions: sensitivity (how often the test catches a true positive) and specificity (how often it correctly identifies someone who does not have antibodies). A large meta-analysis of serological tests found that lab-based methods like ELISA had a pooled sensitivity of about 84% for detecting IgG or IgM, while the less complex lateral flow assays used for rapid point-of-care testing came in around 66%. Specificities across all methods were high, generally above 96%.4PubMed. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis
In plain terms, the chance of a false positive is low with most tests. The bigger risk is a false negative, especially if the test is taken too early. One study found that the sensitivity of a rapid lateral flow test was only 43% in patients overall but climbed to 60% when restricted to patients who had been symptomatic for at least a week.5PubMed Central. Comparison of diagnostic accuracies of rapid serological tests and ELISA to molecular diagnostics in patients with suspected coronavirus disease 2019 presenting to the hospital Timing is the single biggest factor in test accuracy: if you test during the first week of illness, your body may not have made enough IgG yet to cross the test’s threshold.
Why Some People Never Test Positive
A small fraction of people with confirmed SARS-CoV-2 infection never develop detectable IgG antibodies at all. Researchers have specifically looked into these non-responders. In one analysis, patients who failed to seroconvert had viral loads and symptom durations similar to those of patients who did. Their total immunoglobulin levels were normal, and standard immune-cell panels showed no obvious deficiency.6PLOS ONE. Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders In other words, these were immunologically normal people whose IgG simply never reached measurable levels. The reasons are not fully understood but likely involve individual variation in how each person’s B cells and helper T cells coordinate.
False negatives can also arise for technical reasons: the wrong timing, the wrong test target, or interference from substances in the blood such as rheumatoid factor or other endogenous molecules.7PubMed Central. Potential false-positive reasons for SARS-CoV-2 antibody testing and its solution If you are convinced you had COVID but your IgG test is negative, timing, test format, and individual biology are all plausible explanations before concluding you were never infected.8PubMed. COVID-19 Antibody Tests and Their Limitations
The Numbers Problem and BAU/ml
If you receive a quantitative IgG result, it will come with a number. The trouble is that the number means different things depending on which manufacturer’s test was used. Different assays use different proprietary scales, and even after converting results to the WHO’s standardized unit (BAU/ml, or binding antibody units per milliliter), the values can differ substantially. One comparison found that the same set of serum samples produced maximum values ranging from about 408 BAU/ml on one platform to nearly 2,000 BAU/ml on another.9PubMed Central. Comparison of the measured values of quantitative SARS-CoV-2 spike antibody assays
This means you should not compare a number from one test to a number from a different test, and you should be cautious about comparing your result to any threshold you find online unless the same assay platform was used. If your doctor orders serial tests to track your antibody trend over time, it is important that the same test from the same lab is used each time.
Does a Higher IgG Number Mean Better Protection
This is the question most people really want answered, and the honest answer is: partially, but it is not straightforward enough for individual decision-making. At the population level, higher anti-spike IgG levels do correlate with better protection. Anti-spike IgG shows a strong statistical correlation with neutralizing activity, the real-world ability of antibodies to block the virus from entering cells.10PubMed Central. Activation of SARS-CoV-2 neutralizing antibody is slower than elevation of spike-specific IgG, IgM, and nucleocapsid-specific IgG antibodies And binding antibody levels have been identified as a useful predictor of vaccine effectiveness, with one analysis estimating a protective threshold for wild-type virus at roughly 60 to 154 BAU/ml depending on which vaccines were included.11PubMed Central. Towards a population-based threshold of protection for COVID-19 vaccines
But these are population-level correlations, not guarantees for any individual. Binding antibody assays measure how well antibodies stick to a viral protein in a lab dish, and antibodies against one part of the spike protein (the receptor-binding domain, for instance) contribute more to virus blocking than antibodies against other parts. Two people with the same IgG number could have very different mixes of antibodies with very different neutralizing power. This is precisely why the U.S. FDA cautioned that currently authorized antibody tests should not be used to evaluate an individual’s level of immunity.12JAMA. The Flawed Science of Antibody Testing for SARS-CoV-2 Immunity
Antibodies also tell only part of the protection story. T cells, memory B cells, and other arms of the immune system play crucial roles in preventing severe disease even when antibody levels are low. A blood test measuring IgG is a snapshot of one dimension of a multi-dimensional defense.
How Quickly Do IgG Levels Fade
After peaking, IgG levels decline. But the rate of decline depends heavily on whether immunity came from infection, vaccination, or both. After natural infection alone, IgG to the spike protein shows a half-life of roughly four to eight months depending on the modeling approach used.13EClinicalMedicine. Antibody titers against SARS-CoV-2 decline, but do not disappear for several months Neutralizing antibody levels follow a similar downward trajectory, with some individuals who had mild illness dropping to undetectable neutralization within a few months.14Nature Microbiology. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
Hybrid immunity, the combination of prior infection plus vaccination, produces substantially more durable antibodies. One modeling study estimated that the half-life of spike-specific IgG in people with hybrid immunity was roughly double that of people who were only vaccinated: around 448 days versus 222 days, and potentially over two years under some modeling assumptions.15PubMed Central. Quantification of the IgG antibody response half-life for hybrid immunity to SARS-CoV-2 So if you were infected and later vaccinated (or vice versa), your IgG is likely declining more slowly than someone with only one type of exposure.
Declining levels do not necessarily mean declining protection, though. Memory B cells can rapidly ramp up antibody production upon re-exposure, even if resting antibody levels in the blood are low. The IgG titer on your test report is a real-time measurement, not a forecast of what your immune system can mobilize in an emergency.
The Variant Problem
Antibodies trained on one version of the virus may be less effective against mutated versions. This has been one of the defining challenges of SARS-CoV-2 immunity. In convalescent plasma studies, IgG antibodies from people infected with the original wild-type virus neutralized the alpha, gamma, and delta variants at concentrations similar to wild-type, but required considerably higher concentrations against the beta and kappa variants, with 60% of subjects showing poor neutralization of beta.16Scientific Reports. Neutralization activity of IgG antibody in COVID‑19‑convalescent plasma against SARS-CoV-2 variants The more recent Omicron-lineage variants have pushed this evasion further.
What this means for interpreting your test: a positive IgG result confirms that your immune system has seen some form of the virus or vaccine, but it says nothing about how well those particular antibodies match whatever variant is circulating right now. Updated boosters target more recent variants in part to address this mismatch.
Cross-Reactivity With Other Coronaviruses
Humans encounter four common seasonal coronaviruses throughout their lives, and antibodies to those viruses can sometimes cross-react on SARS-CoV-2 tests. Researchers found that SARS-CoV-2 IgG antibodies showed measurable cross-reactivity with the spike proteins of other betacoronaviruses, including the seasonal strains OC43 and HKU1.17PubMed Central. Serologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal Betacoronaviruses However, a separate large-scale study found no consistent pattern of IgG cross-reactivity going the other direction, where antibodies from seasonal coronavirus infections would falsely trigger a SARS-CoV-2 positive result.18Nature Communications. Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity The practical upshot: false positives from cold-virus antibodies are possible in theory but appear to be uncommon with well-designed assays.
How Immunosuppression Affects Results
If you take medications that suppress your immune system, your IgG test results may not follow the typical pattern. A prospective study across a broad range of immunocompromising conditions found that several factors predicted poor antibody responses to vaccination, including the degree of immunosuppression, anti-CD20 monoclonal antibody therapy (drugs like rituximab that deplete B cells), and older age.19Clinical Infectious Diseases. Prospective Evaluation of Coronavirus Disease 2019 Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions In patients with primary antibody deficiencies specifically, age itself was less of a factor in seroconversion, but the underlying immune condition mattered enormously.20PubMed Central. SARS-CoV-2 Vaccine Responses in Individuals with Antibody Deficiency: Findings from the COV-AD Study
People on immunosuppressive therapy for organ transplants, autoimmune diseases, or cancers may test negative or low even after multiple vaccine doses. A study focused on immunocompromised patients receiving mRNA vaccines found that B-cell-depleting therapies and potent immunosuppressive agents were the strongest drivers of poor antibody responses, with a trend toward somewhat better results in patients who were younger or female.21JAMA Oncology. Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients For these individuals, a low or negative IgG does not mean vaccination was pointless; T-cell responses may still offer partial protection, and additional doses or alternative strategies are often recommended.
How Infection and Vaccination Shape Antibodies Differently
Infection and vaccination do not produce identical antibody profiles even when both trigger strong IgG responses. Research at the molecular level has shown that infection tends to generate antibodies more focused on parts of the spike protein outside the receptor-binding domain, while vaccination tilts the response toward the receptor-binding domain itself.22Cell Reports Medicine. Molecular-level analysis of human hybrid immunity and immunological imprinting to SARS-CoV-2 spike This “imprinting” persists even in people who later acquire hybrid immunity. The practical effect is that two people with the same total IgG level may carry antibodies with somewhat different targets and functional strengths depending on their exposure history.
Children’s IgG Responses
Children infected with SARS-CoV-2 tend to produce a narrower antibody response than adults. Research found that while adults generated IgG, IgM, and IgA against both the spike and nucleocapsid proteins, children primarily made IgG against spike alone, with reduced anti-nucleocapsid antibodies and lower overall neutralizing activity.23Nature Immunology. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum However, the antibodies children do produce appear to be qualitatively different in interesting ways: they show higher binding avidity for the spike protein and greater ability to engage certain immune receptors on cell surfaces.24Nature Communications. SARS-CoV-2 antibody responses in children exhibit higher FcR engagement and avidity than in adults So a child’s lower IgG number on a standard test may understate the functional quality of their immune response.
What Blood Tests Miss About Mucosal Immunity
Standard IgG tests use a blood sample, which means they measure antibodies circulating in your bloodstream. They say nothing about what is happening at the mucosal surfaces of your nose and throat, which is where SARS-CoV-2 first enters. Mucosal immunity relies heavily on a different antibody class, IgA, and the kinetics are quite different from what shows up in blood. Research has shown that salivary IgA against the spike protein falls back to baseline within about six months of infection, even while serum IgA remains detectable for over a year.25Frontiers in Immunology. Long-term systemic and mucosal SARS-CoV-2 IgA response and its association with persistent smell and taste disorders Vaccination alone struggled to generate a meaningful mucosal IgA response, though vaccination after a prior infection could temporarily reactivate mucosal antibodies.
This is an important blind spot. A strong IgG result from a blood draw might give you confidence about your systemic immunity, but it reveals nothing about whether your upper airways can mount a rapid local defense against a new exposure. This gap in mucosal protection is one reason breakthrough infections still occur even in people with robust serum antibody levels.
Dried Blood Spot Collection
If you have had a fingerstick antibody test done at home rather than a traditional blood draw, you might wonder whether those results are as reliable. Dried blood spot (DBS) sampling, where a drop of blood is collected on filter paper and mailed to a lab, has been validated against standard venous blood draws. One study found perfect agreement between DBS and venous serum for detecting SARS-CoV-2 IgG.26PubMed. Unlocking the potential of dried blood spot sampling for SARS-CoV-2 antibody detection: A pathway to efficient pandemic surveillance A larger comparison using self-collected DBS samples found about 98% total agreement with serum results, with nearly all discrepancies in the borderline zone where antibody levels were barely above or below the test’s cutoff.27Scientific Reports. Monitoring of SARS-CoV-2 antibodies using dried blood spot for at-home collection Quantitative values from DBS samples tend to run lower than matched serum values because of dilution during the extraction process, but for the binary question of whether you have IgG or not, the method holds up well.